Literature DB >> 2518449

Plasma factors influencing PGI2-like activity in patients with IgA nephropathy and Henoch-Schönlein purpura.

S Túri1, J Nagy, I Haszon, Z Havass, M Németh, C Bereczki.   

Abstract

Plasma factors influencing vascular PGI2-like activity (PSA) were studied in 45 patients with IgA nephropathy, 18 with Henoch-Schönlein purpura, including 8 children with nephrotic syndrome, and 41 controls. The results were compared with the levels of plasma high-density lipoprotein (HDL), low-density lipoprotein (LDL) and fatty acid components of plasma phospholipids. The plasma of 38 of 45 patients with IgA nephropathy and 14 with Henoch-Schönlein purpura showed a diminished ability or no ability to support PSA. Twenty-three patients with IgA nephropathy and 10 with Henoch-Schönlein purpura exhibited an inhibitory activity against PGI2 production. The plasma HDL level was lower, while the LDL level and the LDL/HDL ratio were significantly higher in IgA nephropathy and Henoch-Schönlein purpura cases than in the controls. A high LDL/HDL ratio was associated with a low plasma PSA. The levels of arachidonic acid and its precursor were not lower in the plasma of patients than in the controls. The decreased PGI2 synthesis may play an important role in the pathogenesis of IgA nephropathy and Henoch-Schönlein purpura, but it can not be explained by reduced PG precursors. LDL may have an inhibitory, and HDL a protective effect on PGI2 synthesis.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2518449     DOI: 10.1007/bf00859628

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  34 in total

1.  Abnormalities of vascular prostaglandins in Henoch-Schönlein purpura.

Authors:  S Turi; J J Belch; T J Beattie; C D Forbes
Journal:  Arch Dis Child       Date:  1986-02       Impact factor: 3.791

Review 2.  IgA nephropathy: perspectives on pathogenesis and classification.

Authors:  S N Emancipator; G R Gallo; M E Lamm
Journal:  Clin Nephrol       Date:  1985-10       Impact factor: 0.975

3.  LDL-cholesterol determination in blood serum following precipitation of LDL with polyvinylsulfate.

Authors:  G Assmann; H U Jabs; U Kohnert; W Nolte; H Schriewer
Journal:  Clin Chim Acta       Date:  1984-06-27       Impact factor: 3.786

4.  An inverse correlation between plasma prostacyclin and serum triglycerides.

Authors:  L Viinikka; O Ylikorkala
Journal:  N Engl J Med       Date:  1980-06-19       Impact factor: 91.245

5.  Stimulation of arterial endothelial cell prostacyclin synthesis by high density lipoproteins.

Authors:  L N Fleisher; A R Tall; L D Witte; R W Miller; P J Cannon
Journal:  J Biol Chem       Date:  1982-06-25       Impact factor: 5.157

6.  Accelerated prostacyclin degradation in the thrombotic thrombocytopenic purpura.

Authors:  Y C Chen; B McLeod; E R Hall; K K Wu
Journal:  Lancet       Date:  1981-08-08       Impact factor: 79.321

7.  Disturbances of prostacyclin metabolism in children with hemolytic-uremic syndrome and in first degree relatives.

Authors:  S Túri; T J Beattie; J J Belch; A V Murphy
Journal:  Clin Nephrol       Date:  1986-04       Impact factor: 0.975

8.  Human arterial and venous tissues generate prostacyclin (prostaglandin x), a potent inhibitor of platelet aggregation.

Authors:  S Moncada; E A Higgs; J R Vane
Journal:  Lancet       Date:  1977-01-01       Impact factor: 79.321

9.  Inhibition of neutrophil migration by serum IgA from patients with IgA nephropathy.

Authors:  J Egido; J Sancho; F Lorente; G Fontan
Journal:  Clin Exp Immunol       Date:  1982-09       Impact factor: 4.330

10.  Reduced umbilical and placental vascular prostacyclin in severe pre-eclampsia.

Authors:  G Remuzzi; D Marchesi; C Zoja; D Muratore; G Mecca; R Misiani; E Rossi; M Barbato; P Capetta; M B Donati; G de Gaetano
Journal:  Prostaglandins       Date:  1980-07
View more
  1 in total

1.  Evidence that the interaction between circulating IgA and fibronectin is a normal process enhanced in primary IgA nephropathy.

Authors:  J C Davin; M Li Vecchi; J Nagy; J M Foidart; J B Foidart; G Barbagallo Sangiorgi; M Malaise; P Mahieu
Journal:  J Clin Immunol       Date:  1991-03       Impact factor: 8.317

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.